Research log // GLP-1
Semaglutide started as a diabetes drug. The newest research is about alcohol craving.
An approved GLP-1 receptor agonist, read like logged output: the weight and heart-disease trials, the kidney data, and the frontier findings — every figure cited.
TL;DR
Semaglutide is a real, approved medicine. It copies a gut hormone called GLP-1 (a signal your body makes after you eat that tells you you are full and helps control blood sugar). One injection lasts about a week. Doctors prescribe it for type 2 diabetes and for weight, and large trials show it also lowers the risk of heart attack and stroke [2][3].
The part getting the most attention now is newer: in an early trial, people with alcohol use disorder drank less while taking it [8]. Animal studies point to the brain's reward wiring as the reason [9]. That research is young — promising, not settled.
People report the "food noise" going quiet, real weight loss, and fewer cravings. They also report nausea, sulfur burps, and tiredness. The honest upsides and downsides — including who should be careful — are on the effects page. Nothing here is medical advice, and nothing here is for sale.
What the record shows
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a lab-built copy of the gut hormone GLP-1, re-engineered so one dose lasts about a week instead of about two minutes [12]. It is FDA-approved across several uses: type 2 diabetes, long-term weight management, lowering major heart events in people with established cardiovascular disease, and (2025) metabolic dysfunction-associated steatohepatitis (a serious fatty-liver disease) [11].
The weight result anchors the file. In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% on placebo in adults with overweight or obesity without diabetes [1]. The heart result is just as large in scope: in SELECT (n=17,604) it cut major adverse cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90) in people with cardiovascular disease and obesity but no diabetes [3].
This site logs that record straight. Findings first. Attribution after. No brand names, no sales.
The emerging-research angle
Here is the line worth watching. In a phase-2 randomized trial (n=48) in adults with alcohol use disorder, low-dose semaglutide reduced laboratory alcohol self-administration (grams consumed; beta -0.48, 95% CI -0.85 to -0.11, P=0.01) and predicted greater reductions in heavy drinking over nine weeks [8]. A rodent study found the same direction — less alcohol intake — and traced it to central reward circuitry [9]. A review of GLP-1 receptor agonists in alcohol use disorder reads the early evidence the same way and calls for larger trials [10].
The mechanism makes this plausible rather than surprising. Semaglutide reaches brain appetite and reward circuits — the arcuate nucleus, the area postrema, and mesolimbic reward pathways — which is also where consummatory behavior like drinking is regulated [4]. The full semaglutide and alcohol evidence is on its own page.
A second frontier is body composition. A trial substudy reported that part of the weight lost is lean (muscle) mass, not just fat — the basis for the semaglutide muscle loss page [13].
How it works, in one paragraph
GLP-1 receptor agonism does three things at once. It triggers glucose-dependent insulin release from the pancreas (insulin only when blood sugar is high, which is why hypoglycemia risk is low on its own), suppresses the counter-hormone glucagon, and slows how fast the stomach empties [12]. The weight effect is mostly in the brain: semaglutide activates satiety neurons (POMC/CART) and quiets hunger neurons (NPY/AgRP) in the hypothalamus, lowering food intake without lowering how many calories the body burns [4]. The full mechanism, trial by trial, is in the Semaglutide research.
What this site is
An independent editorial log of the published semaglutide literature. Not a clinic. Not a pharmacy. It does not prescribe, dispense, or sell anything, and it names no products. Every quantitative claim maps to a numbered source in the Semaglutide references. For the human side — reported benefits, reported side effects, and cited cautions — start with Semaglutide effects.